Abeona Therapeutics, Inc. (ABEO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.40-1.57%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Abeona Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	17.7M
EPS	—	-0.131
Annual ending 2026-12-31
Revenue	—	52.63M
EPS	—	-0.968
Annual ending 2027-12-31
Revenue	—	115.62M
EPS	—	-0.184

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
reduce losses and improve free cash flow yield	A supporting condition in Abeona Therapeutics, Inc.'s published investment case. The stated target is move free cash flow yield from -23% toward positive.	Broken	free cash flow yield remains below -10% next year	Valuation inputs unavailable A completed valuation measurement is required. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
achieve EPS >= $1.71 by 2026-06-30	Abeona aims to reach profitability by mid-2026 with EPS of $1.71.	Broken	EPS falls below $1.71 by 2026-06-30	Diluted EPS: $-0.35 per share FY2026-Q2; GAAP. Published target: >=1.71 USD_PER_SHARE. Same fiscal period as the stored target. Source published Aug 13, 2026-0.35 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 5fc9d3a8-8af8-415d-91e3-07ca67f159f1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
double revenue to about $134.9M by 2027-12-31	A primary condition in Abeona Therapeutics, Inc.'s published investment case. The stated target is >=134942830 USD.	Broken	revenue growth falls below doubling by 2027-12-31	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.18

Unavailable → $-0.18 · observed estimates

FY2027 revenue$0.12B

$0.14B → $0.12B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$139,632,714	4 / 5
2026-07-25	Unavailable	$139,632,714	4 / 5
2026-07-26	Unavailable	$139,632,714	4 / 5
2026-07-27	Unavailable	$139,632,714	4 / 5
2026-07-28	Unavailable	$139,632,714	4 / 5
2026-07-29	Unavailable	$139,632,714	4 / 5
2026-07-30	Unavailable	$134,942,830	3 / 6
2026-07-31	Unavailable	$134,942,830	3 / 6
2026-08-01	Unavailable	$134,942,830	3 / 6
2026-08-02	Unavailable	$134,942,830	3 / 6
2026-08-03	Unavailable	$134,942,830	3 / 6
2026-08-04	Unavailable	$134,942,830	3 / 6
2026-08-05	Unavailable	$134,942,830	3 / 6
2026-08-06	Unavailable	$134,942,830	3 / 6
2026-08-07	Unavailable	$134,942,830	3 / 6
2026-08-08	Unavailable	$134,942,830	3 / 6
2026-08-09	Unavailable	$134,942,830	3 / 6
2026-08-10	Unavailable	$134,942,830	3 / 6
2026-08-11	Unavailable	$139,632,714	4 / 5
2026-08-12	Unavailable	$134,942,830	3 / 6
2026-08-13	Unavailable	$134,942,830	3 / 6
2026-08-14	Unavailable	$139,632,714	4 / 5
2026-08-15	Unavailable	$139,632,714	4 / 5
2026-08-16	Unavailable	$139,632,714	4 / 5
2026-08-17	Unavailable	$139,632,714	4 / 5
2026-08-18	Unavailable	$139,632,714	4 / 5
2026-08-19	Unavailable	$139,632,714	4 / 5
2026-08-20	Unavailable	$139,632,714	4 / 5
2026-08-21	Unavailable	$119,212,143	4 / 6
2026-08-22	Unavailable	$119,212,143	4 / 6
2026-08-23	Unavailable	$119,212,143	4 / 6
2026-08-24	Unavailable	$119,212,143	4 / 6
2026-08-25	Unavailable	$118,863,000	4 / 6
2026-08-26	Unavailable	$118,863,000	4 / 6
2026-08-27	Unavailable	$118,863,000	4 / 6
2026-08-28	Unavailable	$118,863,000	4 / 6
2026-08-29	Unavailable	$118,863,000	4 / 6
2026-08-30	Unavailable	$118,863,000	4 / 6
2026-08-31	Unavailable	$118,863,000	4 / 6
2026-09-01	Unavailable	$118,863,000	4 / 6
2026-09-02	Unavailable	$118,863,000	4 / 6
2026-09-03	Unavailable	$118,863,000	4 / 6
2026-09-04	Unavailable	$118,863,000	4 / 6
2026-09-05	Unavailable	$118,863,000	4 / 6
2026-09-06	Unavailable	$118,863,000	4 / 6
2026-09-07	Unavailable	$118,863,000	4 / 6
2026-09-08	Unavailable	$118,863,000	4 / 6
2026-09-09	Unavailable	$118,863,000	4 / 6
2026-09-10	Unavailable	$118,863,000	4 / 6
2026-09-11	Unavailable	$118,863,000	4 / 6
2026-09-12	Unavailable	$118,863,000	4 / 6
2026-09-13	Unavailable	$118,863,000	4 / 6
2026-09-14	Unavailable	$118,863,000	4 / 6
2026-09-15	Unavailable	$118,863,000	4 / 6
2026-09-16	Unavailable	$118,863,000	4 / 6
2026-09-17	Unavailable	$118,863,000	4 / 6
2026-09-18	Unavailable	$118,863,000	4 / 6
2026-09-19	$-0.09	$121,217,625	5 / 6
2026-09-20	$-0.09	$121,217,625	5 / 6
2026-09-21	$-0.09	$121,217,625	5 / 7
2026-09-22	$-0.09	$121,217,625	5 / 7
2026-09-23	$-0.09	$121,217,625	5 / 7
2026-09-24	$-0.09	$121,217,625	5 / 7
2026-09-25	$-0.09	$121,217,625	5 / 7
2026-09-26	$-0.09	$121,217,625	5 / 7
2026-09-27	$-0.09	$121,217,625	5 / 7
2026-09-28	$-0.09	$121,217,625	5 / 7
2026-09-29	$-0.09	$121,217,625	5 / 7
2026-09-30	$-0.09	$121,217,625	5 / 7
2026-10-01	$-0.09	$121,217,625	5 / 7
2026-10-02	$-0.09	$121,217,625	5 / 7
2026-10-03	$-0.09	$121,217,625	5 / 7
2026-10-04	$-0.09	$121,217,625	5 / 7
2026-10-05	$-0.09	$121,217,625	5 / 7
2026-10-06	$-0.09	$121,217,625	5 / 7
2026-10-07	$-0.09	$121,217,625	5 / 7
2026-10-08	$-0.18	$115,622,125	5 / 7
2026-10-09	$-0.18	$115,622,125	5 / 7
2026-10-10	$-0.18	$115,622,125	5 / 7
2026-10-11	$-0.18	$115,622,125	5 / 7
2026-10-12	$-0.18	$115,622,125	5 / 7
2026-10-13	$-0.18	$115,622,125	5 / 7
2026-10-14	$-0.18	$115,622,125	5 / 7
2026-10-15	$-0.18	$115,622,125	5 / 7
2026-10-16	$-0.18	$115,622,125	5 / 7
2026-10-17	$-0.18	$115,622,125	5 / 7
2026-10-18	$-0.18	$115,622,125	5 / 7
2026-10-19	$-0.18	$115,622,125	5 / 7
2026-10-20	$-0.18	$115,622,125	5 / 7
2026-10-21	$-0.18	$115,622,125	5 / 7
2026-10-22	$-0.18	$115,622,125	5 / 7
2026-10-23	$-0.18	$115,622,125	5 / 7
2026-10-24	$-0.18	$115,622,125	5 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	6	0	0
2026-06-01	6	0	0
2026-07-01	6	0	0
2026-08-01	6	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

reduce losses and improve free cash flow yieldPublished status: Broken
achieve EPS >= $1.71 by 2026-06-30Published status: Broken
double revenue to about $134.9M by 2027-12-31Published status: Broken

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.8%Typical daily move · historical

Downside history

-41.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Abeona Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

ABEO is a speculative growth company built around expanding ZEVASKYN’s commercial launch, not a profitable compounder today. Its multi-year view is intact, but the evidence is mixed: launch progress is on track while profitability remains unproven.

What's priced into Abeona Therapeutics, Inc.

The valuation is described as cheap, and the priced-in tag is justified, with no fragility gates triggered. However, the model has low confidence, and its expectations gap is slightly negative, meaning expectations are not clearly below the evidence. The valuation is also 1.24 times the peer level, so the cheap label does not mean it is cheaper than peers.

What the fundamentals likely do

Near term, ZEVASKYN revenue rose from $8.7 million in Q1 2026 to $11.4 million in Q2, and the treatment-center network expanded, supporting continued commercial progress. But net losses widened from $17.1 million to $20.2 million across those quarters, leaving management’s first-half profitability goal at risk. Near-term earnings risk is elevated, with a 57% estimated miss probability, and the August earnings miss adds to that concern.

What Abeona Therapeutics, Inc. hinges on

Over the next few quarters, the central test is whether ZEVASKYN revenue and treatment access keep growing enough to narrow losses. A guidance cut would be a meaningful negative, while continued weak employment could increase pressure on cyclical healthcare names. Strong earnings and guidance from sector peers could support the sector backdrop, though that would not resolve ABEO’s company-specific profitability challenge.